Schonfeld Strategic Advisors LLC bought a new position in shares of Haleon plc (NYSE:HLN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 137,652 shares of the company's stock, valued at approximately $1,313,000.
Several other institutional investors and hedge funds have also made changes to their positions in HLN. Sierra Ocean LLC purchased a new position in Haleon in the 4th quarter worth about $26,000. Versant Capital Management Inc grew its stake in Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock worth $34,000 after acquiring an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Haleon during the fourth quarter worth approximately $35,000. Spire Wealth Management bought a new stake in shares of Haleon during the fourth quarter valued at approximately $39,000. Finally, FIL Ltd boosted its holdings in shares of Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after purchasing an additional 1,270 shares during the period. 6.67% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
HLN has been the topic of several research reports. Morgan Stanley upgraded Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective on the stock in a report on Friday. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a report on Monday, March 3rd. HSBC reiterated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Finally, Barclays reiterated an "overweight" rating on shares of Haleon in a research note on Tuesday, May 6th. Five investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $11.25.
Get Our Latest Analysis on HLN
Haleon Stock Down 0.4%
Shares of NYSE HLN traded down $0.05 during trading hours on Monday, hitting $10.69. 7,311,293 shares of the stock were exchanged, compared to its average volume of 7,762,480. The company has a market cap of $48.23 billion, a PE ratio of 31.40, a PEG ratio of 2.82 and a beta of 0.24. Haleon plc has a 12 month low of $8.24 and a 12 month high of $10.85. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a fifty day moving average price of $10.20 and a 200-day moving average price of $9.84.
Haleon (NYSE:HLN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. On average, sell-side analysts expect that Haleon plc will post 0.43 EPS for the current year.
Haleon Increases Dividend
The firm also recently declared a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a $0.1166 dividend. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, April 25th. This is a positive change from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is currently 58.97%.
About Haleon
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
See Also
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
